Agenus (NASDAQ:AGEN) Given “Buy” Rating at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I reissued their buy rating on shares of Agenus (NASDAQ:AGEN – Get Rating) in a report published on Wednesday, Benzinga reports. The firm currently has a $8.30 price target on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a buy rating and issued a $8.00 price target on shares of Agenus in a research note on Tuesday, February 28th. One research analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Agenus has a consensus rating of Moderate Buy and a consensus target price of $7.10.

Agenus Stock Performance

Shares of NASDAQ AGEN opened at $1.70 on Wednesday. Agenus has a 12 month low of $1.25 and a 12 month high of $3.37. The firm has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $2.44.

Hedge Funds Weigh In On Agenus

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Trellus Management Company LLC bought a new stake in Agenus during the 3rd quarter worth approximately $1,230,000. Lazard Asset Management LLC raised its position in shares of Agenus by 1,321.3% during the third quarter. Lazard Asset Management LLC now owns 1,153,038 shares of the biotechnology company’s stock valued at $2,363,000 after buying an additional 1,071,912 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Agenus during the third quarter valued at approximately $157,000. Lynch & Associates IN grew its holdings in shares of Agenus by 62.3% in the fourth quarter. Lynch & Associates IN now owns 45,580 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 17,500 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its holdings in shares of Agenus by 32.3% in the third quarter. Los Angeles Capital Management LLC now owns 1,092,218 shares of the biotechnology company’s stock valued at $2,239,000 after purchasing an additional 266,467 shares in the last quarter. Hedge funds and other institutional investors own 53.81% of the company’s stock.

About Agenus

(Get Rating)

Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.